Idiopathic pulmonary fibrosis (IPF) is the most severe form of lung fibrosis. It is progressive, and has an extremely poor outcome and limited treatment options. The disease exclusively affects the lungs, and thus less attention has been focused on blood-borne immune cells.
INTRODUCTION
Fibroproliferative diseases, including the various fibrotic lung diseases, systemic sclerosis, liver cirrhosis and macular degeneration, are leading causes of morbidity and mortality.
Idiopathic pulmonary fibrosis (IPF) is the most severe form of chronic fibrotic lung disease (1) .
Unlike some of the other fibrotic diseases, IPF, is an unremitting, progressive disease, with a median survival of only five years from diagnosis (2, 3) . It is the outcome of a complex interaction of genetic and environmental factors, ageing-associated processes and epigenetic reprogramming. Repeated but minor insults to the alveolar epithelium, for example by gastrooesophageal reflux, viral infection or cigarette smoking, are thought to lead to a disproportionate repair response by fibroblasts and mesenchymal cells (4) . This aberrant wound healing response results in parenchymal damage, an expanded collagen-rich interstitium and alveolar destruction which ultimately leads to impaired gas exchange.
Research has focused more intensely on the aberrant repair response, and less on the causes of injury and drivers of chronic fibrosis. This has led to more than 40 clinical trials, but only two drugs (Nintedanib and Pirfenidone), which slow down but do not halt progression of disease (1) . A better understanding of the initiators and immune drivers of fibrosis in IPF will increase the range of new therapeutic targets for this condition.
There is ample evidence that tissue macrophages are involved in fibrogenesis (5) (6) (7) .
Abnormalities in macrophages can lead to aberrant repair due to anomalous cross-talk with stromal cells (including epithelial cells, endothelial cells, fibroblasts, and progenitor cells), with exuberant production of inflammatory mediators and growth factors (6) . Recent single cell technology has also indicated that there are specific pro-fibrotic macrophage subsets (in murine models), which drive fibroblast proliferation by secreting platelet-derived growth factor (PDGF) (8) . Unsurprisingly, lung macrophages have been proposed as a therapeutic target in IPF (9) . However, in practice, these lung-based cells, some, in dense matrix-rich interstitium (10) may be poorly accessible to potential drugs. In contrast, a cellular target in the blood, show to be linked to fibrosis in the lungs could be an ideal drug focus. In this regard, the precursor of lung macrophages -the circulating monocyte, is of immense interest.
Monocytes play important roles in immune defense, inflammation and homeostasis (11) .
Typically, they are quickly mobilized to sites of injury or infection where they contribute to the initial inflammatory processes and instigate adaptive immune responses. Once in tissues, they rapdily differentiate into macrophages in response to local environmental cues (12) , producing macrophages with specific functions, e.g. macrophages that facilitate healing or those that restore tissue homeostasis after lung injury (13) (14) (15) . Monocyte-derived, rather than embryonically-derived alveolar macrophages, have now been clearly shown to be critical for the development of lung fibrosis (in mice), and potentially also in the resolution of fibrosis (5, 16) Relatively little is known about the contribution of monocytes per se (rather than macrophages) to lung fibrosis in human disease. These immune cells are largely inflammatory and injurious though can also aid repair of damaged tissue. In organs other than lungs, animal studies have described the ability of monocytes to enhance myofibroblast proliferation in cardiac muscles after infarction (17) , and to promote progenitor regrowth after eye and spinal cord injury mediated via production of IL-10 (18) . In recent years, it has also become clear that during conditions of immune 'stress' e.g. severe inflammation or cancer, the generation of monocytes in the bone marrow can bypass canonical routes to produce immature forms with altered function, some with pro-fibrotic features (19) . Thus, monocytes in their own right, could be important effectors in fibrosis, both by causing or enhancing injury, and thus driving repair, and also by differentiating into pro-fibrotic macrophages. A recent study has shown increased levels of circulating monocytes in IPF patients, which was associated with poorer survival, but not a potential mechanism for how monocytes might contribute to pathogenesis, nor a direct link to fibrosis (42) .
In this study, we investigate whether monocytes in IPF patients bear abnormalities that might contribute to the pathogenesis of IPF. We found that circulating monocytes levels correlated directly with the extent of fibrosis in the lungs. In addition, they are phenotypically distinct, displaying increased expression of CD64, a type 1 IFN signature in their transcriptome and a greater magnitude of type 1 IFN response when stimulated. These abnormalities are accompanied by markedly raised CSF-1 levels in the serum and prolonged survival of monocytes ex vivo. Our study defines the key monocytic abnormalities in IPF, proposing type 1 IFN-primed monocytes as possible mediators of injury, and a potential driver of an aberrant repair response and fibrosis. It provides a rationale for monocytes as a therapeutic target in IPF.
RESULTS

Circulating monocytes levels in IPF correlate with the extent of lung fibrosis and display increased expression of CD64
Patients with rigorously defined IPF (see Supplemental Methods), were recruited from the Oxford Interstitial Lung Disease Clinical Service (n=37). Current smokers (or ex-smokers within 5 years), those on immunosuppressants or corticosteroids, and those with concomitant lung disease or immune conditions or cancers were excluded (demographics in Supplemental Table 1 ). 14 patients were on the anti-fibrotic drug (Pirfenidone); no patients were on immunosuppressants or corticosteroids. Data were analysed for all IPF patients (n=37) vs age-matched healthy controls (HC) (n=28), and also after dividing patients into those on Pirfenidone treatment (n=14) compared to those without (n=14).
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll separation and analysed immediately without storage. Monocytes were defined as CD14 lo-hi CD16 neg-hi cells ( Figure 1A ).
In support of Scott's findings (42) , total monocytes levels were higher in IPF patients compared to age-matched heathy controls (HC); both when quantified as % of PBMCs ( Figure 1A ) and absolute number (per ml of blood) ( Figure 1B) [16%(5) v 12%(6); IPF vs HC; p=0.022 and 3.2x10^5 (1.6) v 1.7x10^5 (0.7)/ml; p<0.001 respectively; mean(S.D.)]. There was no difference comparing patients on Pirfenidone to those who were not ( Figure S1a To examine the correlation between monocyte frequency and the extent of lung fibrosis we used a scoring method to quantify the amount of fibrosis in IPF lungs in a subset of patients (n=19). The score comprised the sum extent of reticulation, honeycombing and traction bronchiectasis [archetypal features of usual interstitial pneumonia (UIP) pattern fibrosis in IPF lungs] on high resolution thoracic computer tomographic (HRCT) scans (see Supplemental Methods). We found that the extent of fibrosis in the patients' lungs correlated positively with levels of circulating monocytes ( Figure 1C ). There was an even stronger correlation between monocyte levels and total amount of honeycombing on HRCT scans ( Figure 1D ). Although not statistically significant, there was also a trend between higher monocyte levels and worse lung function -forced vital capacity (FVC) and diffusion capacity (TLCO) ( Figure 1E -F). As TLCO and FVC can be affected by factors other than the amount of fibrosis (e.g. cardiac failure, obesity and emphysema), these results suggest that monocyte level in specifically linked to the extent of lung fibrosis.
During the study period, we were also able to recruit 10 patients who were hospitalised with acute exacerbation of IPF (AEIPF), a distinct and severe episode of acute clinical deterioration, characterised by a picture of massive injury on CT scan (20) (see Supplemental Methods). These patients had evidence of typical changes (ground glass opacification) on CT scan and no evidence of infection by aerobic and anaerobic blood cultures. Monocyte levels were measured in these patients and found to be significantly higher than in stable IPF patients [25%(12) v 16%(5); IPF vs AEIPF; p<0.001] (Figure1G and Supplemental Table 2A ,B).
We next immunophenotyped the circulating monocytes, starting with the classical division of monocytes to classical, non-classical and intermediate subtypes (11) . We found no difference in the proportion of intermediate (CD14 hi CD16 hi ), non-classical (CD14 mid CD16 hi ) and classical (CD14 hi CD16 neg/mid ) subsets ( Figure 1I ) between IPF and HC. Further flow cytometry analysis focusing on phenotypic markers which might confer greater inflammatory (M1-like -CD64, CD62L, CCR7) or pro-repair (M2-like -CD163) features (21) showed no abnormality apart from an increase in CD64 expression ( Figure 1H -L, Supplemental Fig 1C) . To complement these flow cytometry studies, gene expression (by qPCR) of M1, M2, M2a, and M2c genes [Supplementary Table 3 (21)] was also examined in freshly isolated monocytes from IPF (n=7) vs age-matched healthy controls (n=8) (demographics and RIN of RNA in Supplemental Table   4 ). We observed no difference in expression in these genes compared to controls -[TGFB1, MRC1 (CD206), CD200R1, TGM2, CD163, IDO1, TNFA, IL6, CXCL10, CCR2 and IL1R2] (Supplemental Figure 1D ) (21).
In summary, we show for the first time, in a carefully conducted study on fresh samples from patients not on immunosuppressants or corticosteroids, that monocytes levels correlated positively with extent of fibrosis in the lungs of IPF patients. Against a wide immunophenotyping screen, we observed an isolated increase in expression of CD64, a highaffinity IgG receptor (FcγRI) that triggers monocyte activation upon receptor aggregation.
Overexpression of CD64 on monocytes has been linked to both inflammatory markers and disease severity in rheumatoid arthritis (22, 23) and systemic lupus erythematosus (24). To date, it has not been associated with fibroproliferative diseases such as IPF.
Serum analysis in IPF patients shows changes that specifically reflect monocyte activity and promote monocyte generation and survival
To explore possible causes for, and consequence of, increased monocyte levels and raised monocytic CD64 expression, we examined key inflammatory and monocyte-associated factors (by multi-plex bead array) in serum from IPF patients (n=24) and healthy controls HCs (n=11) (demographic in Supplemental Table 5 ; 8 patients were on the antifibrotic, Pirfenidone).
A set of 13 cytokines and chemokines were selected to reflect the following functional groups- Figure 2E ).
We did not observe any significant correlation between monocyte levels and any soluble mediators, nor between monocytic CD64 expression and any soluble mediators, apart from a modest but significant positive correlation between CSF-1 levels and monocytic CD64 expression in IPF patients (Supplemental Figure 2F -G).
These results show that the blood compartment in IPF patients demonstrated clear anomalies in monocyte-associated but not in lymphocytic and granulocyte-related immune mediators.
Very high levels of CCL2 and IL-6 may be products of activated monocytes (25-28) while the markedly increased CSF-1 levels point to an environment that is pro-monocyte generation and survival (29) .
RNA sequencing reveals a Type 1 IFN signature in monocytes from IPF patients
In order to further investigate the abnormal monocyte phenotype detected in IPF patients, we subjected monocytes from IPF and age-matched healthy controls to bulk RNA sequencing.
Monocytes were isolated by CD14 + magnetic bead selection (98-99% purity) from three wellcharacterised IPF patients (with definite UIP pattern fibrosis on CT scan) who were not on anti-fibrotics, and were non-smokers (all male; aged 57,76 and 78y) and three healthy controls (HC) (non-smokers, no medications; aged 65,68 and 71y; all males).
We focused on identifying the processes that underlie the transcriptomic changes between IPF patients and controls, rather than individual differentially expressed genes. We first subjected the differentially expressed gene list to enrichment analysis, using gene sets from the REACTOME platform, a database of signalling and metabolic molecules, organized into biological pathways and processes, with a focus on reactions. This revealed that the most significantly enriched gene sets were 'IFN signalling' and 'IFNab signalling' ( Figure 3A and Supplemental Table 6 ). We tested this further by using Gene Set Enrichment Analysis (GSEA) (30) which analysed enrichment of all genes arranged according to fold change, compared to the control group, regardless of statistical significance of their differential expression. This approach also identified type 1 IFN signalling gene sets as the most enriched gene sets in IPF, using both REACTOME and GO gene sets ( Figure 3B and Supplemental Table 7 ).
To explore the composition of the most highly enriched gene sets, we examined the genes that made up the core enrichment genes (i.e. the genes that contribute most to the enrichment result) in the five IFN signalling gene sets shown in Figure 3B . From these five gene sets, we observed that most of the genes were interferon stimulated genes (ISGs) from different points in the type 1 IFN signalling pathway ( Figure 3D Indeed, when we examined the expression of a curated gene set of 16 archetypal ISGs [from (33) and (34) ] and six ISGs found increased in PBMCs from patients with Aicardi-Goutières syndrome, [often referred to as the type 1 IFN signature (IFI27, ISG15, IFI44L, IFIT1, SIGLEC1 and RSAD2)] (35), all these ISGs were also increased in IPF patients compared to HC ( Figure 3F ).
Thus, RNA sequencing of IPF monocytes showed that their gene expression profiles were endowed with a type 1 IFN signature. This has not been hitherto reported and is highly relevant to the observation of increased CD64 expression as type 1 IFNs can induce CD64 expression on monocytes (36) , and CD64 is a biomarker of disease activity in type 1 interferonopathies like SLE (36, 37) 
Monocytes from IPF patients show greater ISG induction in response to type 1 IFN stimulation
The RNA sequencing findings suggest that monocytes from IPF patients have a primed type I IFN signalling pathway. To test this, we reasoned that IPF monocytes would respond more readily or greatly to a type I IFN stimulus. We recruited a larger cohort of IPF patients (n=27) and age-matched healthy controls (n=10), recruited on the same basis as described above (Supplemental Methods; demographics in Supplemental Table 8A ). We examined gene expression by qPCR, of the most differentially expressed ISGs from our RNA sequencing data -IFI27, USP18, MX1 and OASL; archetypal ISGs (IRF7 and MX2) and four ISGs found highly expressed in PBMCs from the type 1 interferonopathy Aicardi-Goutières syndrome (AGS) patients -IFI27, ISG15, IFI44L and RSAD2 (38) . In addition, IFNB1 and STAT1, a key transcription factor in the type I IFN signalling pathway were also examined.
We found that all the ISGs, STAT1 and IFNB1 showed higher expression in IPF compared to control, consistent with the RNA sequencing findings, with some statistically significantly increased -MX2, ISG15 and OASL (p=0.021, p=0.048 and p=0.048 respectively) ( Figure 4A -K). There was no difference in findings between patients on anti-fibrotics (Pirfenidone and Nintedanib) and those not (Supplemental Figure 4A -K). As expected, expression levels of ISGs in each patient's monocytes correlated strongly with each other, i.e those patients with high MX1, also had high IRF7 and all other tested ISGs (Supplemental Figure 4T ). Basal ISG expression levels were also significantly correlated with basal IFNB1 and IFNAR1 expression (Supplemental Figure 4T ). These results provide support for the integrity of the data as these genes are expected to change contemporaneously. It is noted that neither IFNB1 nor IFNAR1 expression was significantly increased in IPF monocytes at homeostasis.
To explore whether CD64 expression were linked to type 1 IFN signalling, contemporaneous basal expression of CD64 (FCGR1B) and representative ISGs (MX1 and ISG15) were also examined. In patients where CD64, MX1 and ISG15 gene expression in monocytes was measured concurrently, we observed a strong positive correlation between all three genes, supporting the link between CD64 expression and type 1 IFN signalling ( Figure 4L -M). In this experiment, as an internal control, MX1 expression was tested against ISG15, and as expected, expression of these ISGs correlated positively and very closely with each other attesting to the rigour of the data ( Figure 4N ).
Next, we tested if monocytes showed an enhanced response to type 1 IFN stimulation. Freshly isolated monocyte from IPF patients (n=20) and HCs (n=10) ( Supplemental Table 8B ) were stimulated with 100U/mL recombinant human IFN-b for 18 hours and expression of key ISGs, IFNA and IFNB1 were examined.
Upon stimulation with type I IFN, both IPF and HC, as expected, monocytes showed increased expression of ISGs when compared to unstimulated monocytes ( Figure 4O -V). The increase was significantly greater in IPF monocytes for MX1, MX2; ISG15 and IFI44L (p=0.010, p=0.007, p= 0.008 and p= 0.029 respectively) ( Figure 4N As with basal level changes, the expression of ISGs after IFN-b stimulation was also strongly correlated with each other. The strongest links were between stimulated MX2 and IFI44L; MX1 and MX2, and MX1 and IFI44L (all p<0.001) (Supplemental Figure 4U ), providing internal control for the data.
These findings suggest that IPF monocytes are primed to respond to type 1 IFN stimulation at homeostasis, and accordingly, respond in a heightened manner when cultured with recombinant IFN-b. Importantly, CD64 expression appear to be linked to basal type 1 IFN priming, supporting the suggestion that CD64 is a marker of the type 1 IFN signature found in IPF monocytes.
Monocytes from IPF patients showed impaired differentiation to macrophages
In the final study, we evaluated the potential impact of our observed monocyte abnormalities in IPF patients on monocyte-derived macrophages (MDMs). Freshly isolated monocytes from IPF and HCs were differentiated to MDMs over 7 days using 10% autologous serum.
As CSF-1 has been shown to influence the differentiation of monocytes towards an M2 macrophage phenotype (39) (40) (41) , we first examined whether IPF MDMs exhibited M2 features.
We found no M2 phenotypic bias on MDMs after 7 days of culture -there was no difference in CD163 or CD200R expression on MDMs derived from IPF patients (n=17) compared to HCs (n=19) ( Figure 5A-B ). We also analysed the expression of CD64 on MDMs but found that both IPF and HC MDMs showed reduced levels of CD64 expression as they differentiate To further support these data, we analysed the ability of monocytes to differentiate into macrophages by examining three prototypical macrophage functions -(i) endogenous production of reactive oxygen species (ROS), (ii) efferocytosis and (iii) phagocytosis. In keeping with a less mature or differentiated macrophage phenotype, IPF MDMs showed significantly lower rates of the archetypal macrophage functions-cellular oxidant levels ( Figure   5E ), efferocytosis ( Fig 5F) and phagocytosis ( Figure 5G ) (Supplemental Table 9 for demographics of recruited patients).
These results show that monocytes from IPF patients differentiated to macrophages less readily and therefore remained monocytes for longer. This is likely to have several implications in the repair, fibrotic and immune defence capacity in IPF (16) . However, here, we were particularly interested in exploring if it might be linked to enhanced type 1 IFN signalling in IPF monocytes. To test this, we used monocytic CD64 expression as a reflection of type 1 IFN signalling (as suggested in Figure 4L -M), and MDM CD14 expression as marker of macrophage differentiation [Supplemental Figure 5A -B] and questioned if monocytes expressing high CD64 subsequently showed lesser ability to differentiate into macrophages (MDM with higher CD14 levels indicate more monocytic feature). We found this to be the case, CD64 expression on the initial monocytes strongly and positively correlated with the retention of CD14 on MDMs differentiated from these monocytes ( Figure 5K ).
To explore whether there was evidence to support persistence of monocytes in tissue, we examined the number of monocytes and macrophages in IPF and healthy controls. Biopsy samples from IPF lungs (n=4) were compared to non-fibrotic lung tissue taken from areas distant to resected lung margins in localised lung cancer with no lymph node spread or metastasis (Table S10 for demographic details). Monocytes and macrophages were identified using immunofluorescence staining as follows: monocytes were CD14 + CD206 neg ; mature macrophages were CD14 neg CD206 + and differentiating monocyte/macrophages were CD14 + CD206 + .
IPF lung samples showed a clearly expanded interstitium with large numbers of CD14 + and CD206 + monocyte/macrophages in the alveolar space ( Figure 5L ). This monocyte/macrophage population was not seen in non-fibrotic lungs ( Figure 5M ). Cells in the IPF samples appeared clustered together ( Figure 5L ), and on high magnification, were revealed to be a combination of monocytes (CD14 + CD206 -), maturing macrophages (CD14 + CD206 + ) and mature macrophages (CD14 -CD206 + ) cells ( Figure 5N ). To quantify CD14 expressing cells, an application was created using the Visiopharm Integrator System® platform where a standardised area of each lung slide was analysed for CD14-expressing cells (Supplemental Figure 6A -D) using pre-defined optimised machine-based algorithm (see Methods). This method did not differentiate between monocytes (CD14 + CD206cells) and differentiating macrophages (CD14 + CD206 + cells). However, it was clear that CD14 expressing cells (representing both monocytes and differentiating monocyte/macrophages) were significantly higher in IPF compared to control lungs [1104 (+/-471) vs 433 (147) cells in 0.25cm 2 ; p=0.03] ( Figure 5O ).
Taken together, these studies suggest that IPF monocytes have decreased capacity to differentiate to monocyte-derived macrophages and this is supported by presence of higher numbers of CD14 + cells in the lungs.
DISCUSSION
Our results show for the first time, that IPF monocytes are endowed with a type 1 IFN gene expression signature and a primed type I IFN pathway, denoted by a heightened response to type 1 IFN stimulation ex vivo. These monocytes also displayed impaired capacity to differentiate to macrophages ex vivo, indicating increased longevity in survival as monocytes, in the lungs. These abnormalities appear linked to each other -monocytic ISG expression at baseline correlated significantly with expression levels of CD64, which in turn is inversely linked to the monocytes' ability to differentiate to macrophages ( Figure 4L -M, and 5K respectively).
The frequency of circulating monocytes correlated with the severity of lung fibrosis, while the serum environment (with a markedly increased CSF-1 levels) supports the maturation of promonocytes to monocytes in the bone marrow and the survival of monocytes (29) .
Our findings are important from several perspectives. Firstly, we provide a biological basis for the involvement of monocytes in the pathogenesis of IPF, and therefore stronger justification to explore these cells as potential therapeutic target beyond increased numbers of monocytes shown by both ours and Scott et al's study (42) . Our work also moves the mechanistic focus away from the pathological site of disease (lungs), to upstream pathways (in the blood) that may be contributing to fibrotic processes, potentially implicating the bone marrow, where monocytes are generated.
Enhanced responsiveness to type 1 IFN in monocytes is a highly significant finding for IPF patients. Type 1 IFN signalling is activated by two consecutive pathways. Sensing of self or viral nucleic acid and bacterial pattern-recognition molecular patterns (PAMPS) by TLR4 on the cell surface, or TLR3,7,8,9 in the endosome and other cytosolic sensors (Supplemental Figure 3) results in transcription of type 1 IFNs and some ISGs (31, 32) . The type 1 IFN (endogenously produced by the cell via this pathway or from other cells) then ligates the IFN receptor (IFNAR) and results in hundreds of ISGs which directly interfere with pathogen replication and also activates other immune pathways to combat infection (31, 32) . This highly potent immune defence pathway unleashes a large number of cytokines, chemokines (43) (44) (45) , and also enhances natural killer cell function and high affinity T and B cell responses (46) . In noninfectious settings, Type 1 IFN signalling can be persistently activated [e.g. due to the recognition of self-nucleic acid in SLE and sensing of abnormal nucleic acid species in Aicardia-Goutieres syndrome (AGS) resulting in severe inflammation and clinicopathologic manifestations (35) ]. In health, type 1 IFN signalling is tightly regulated, and its activation is accompanied by restraining pathways to reduce the impact of inflammation and immune activation (46, 47) . Our findings show that IPF monocytes are 'held' in a heightened state of type 1 IFN signalling readiness, with the ability to respond at greater magnitude to type 1 IFN stimulation, which may in turn result in over-exuberant downstream innate and adaptive immune responses. This is an important finding in IPF as it suggests that monocytes have greater capacity to cause injury during an infection or when stimulated by damage-associated molecular patterns (DAMPS) (76) . The former trigger is particularly relevant in AEIPF ( Figure 1H ), a devastating event associated with diffuse alveolar injury, accelerated fibrosis and high mortality.
The cause of AEIPF is unknown but often associated with an infective trigger (48). Trafficking of large numbers of monocytes to the lungs can precipitate injury due to release of inflammatory mediators like IL-6, TNF-a and IL-1b (49). In IPF, injury could be further enhanced by 'supercharged' monocytes primed to respond with an augmented type 1 IFN response. In fact, the diffuse alveolar damage pattern found in lungs during AEIPF (on both histology and CT imaging assessment), is akin to the widespread alveolitis in high-pathogenicity influenza infection where type 1 IFN and monocytes are central causal factors. In a lung microenvironment set for aberrant repair, as in IPF, such injury could lead to the accelerated fibrosis observed in AEIPF, and drive progression of fibrosis as seen in IPF. Delayed differentiation of monocytes to macrophages could mean persistence of pro-injury monocytes in the lung. Indeed, monocytes per se are recognised mediators of inflammation and injury. In other organs (e.g. neuronal damage models), the accumulation of monocytes is associated with extensive secondary axonal death and delayed repair (50). Similarly in the liver, monocyte presence is associated with pathological inflammation (51) . We have also shown previously that very high levels of circulating monocytes are associated with severe respiratory impairment in influenza (52) . Reduced rate of differentiation to macrophages can also have other negative impact on fibrosis. Macrophages are important effector cells in mediating repair and limiting inflammation after the initial stages of injury. They scavenge cellular debris, dying neutrophils and other apoptotic cells, and release IL-10 and other factors that regulate and control extracellular matrix deposition (6, 53) . It is unclear why IPF monocytes showed poorer differentiation capacity but correlation with monocytic CD64 expression suggests that this may be related to enhanced type 1 IFN signalling.
Intriguingly, a murine study that showed type 1 IFN activation in infiltrating monocytes delayed their differentiation to macrophages in the liver during hepatitis C infection, although the mechanism for this was unclear (54) .
Our study did not elucidate the cause of type I IFN signalling priming. We did not observe high levels of IFN-a or b in the serum nor in the transcriptome of IPF monocytes. This could be due to well recognised difficulties in measuring type 1 IFNs at the RNA and protein level, and if so, it is possible that low level type 1 IFN production occurs in IPF patients. Against this possibility is the selection criteria for our patients, which rules out over infection and minimises the chance of subclinical infection. Clinical assessments were undertaken to ensure that there were no symptoms of infections nor evidence of recent clinical deterioration. However, IPF patients have been shown to have greater levels of latent viral particles, e.g. Herpes and Epstein Barr viruses in lung biopsies (55) (56) (57) . Although these viruses tend to be kept in check by T cells, there is evidence that type I IFN signalling may also be involved (58) , so this could potentially be a pathway to a primed type I IFN signalling in these patients. The other possibility is an epigenetic influence on the transcription of type I IFN signalling. The interferon regulatory factors (IRFs) are under epigenetic control (59) and can be modulated epigenetically to increase type I IFN signalling. These possibilities will be interesting to explore in future studies. Increased CD64 expression on monocytes was a key feature of IPF monocytes. This was the only clear phenotypic abnormality that we observed, and its level of expression correlated with serum CSF-1 levels, ISGs (MX1 and ISG15), and the persistence of monocytes in the in vitro studies; linking these findings together. These links and it being a surface protein make increased monocytic CD64 a potentially useful marker for the abnormalities observed in IPF monocytes. CD64 is a high-affinity receptor (FcγRI), which binds the Fc portion of IgG, and is constitutively expressed on monocytes and macrophages. It has also been shown to be an ISG (60, 61) . CD64 on monocytes has been observed to correlate with IFN-a levels in the serum of SLE patients and enhanced type 1 IFN signalling (37) . Selective apoptosis of CD64 hi macrophages in skin inflammation model was associated with resolution of skin inflammation (62) . Of relevance to our findings, using type 1 IFN knockout mice, Fleetwood and colleagues showed that type 1 IFN signalling significantly enhanced CSF-1 production in murine macrophages (41) . Thus the correlation between CD64 and CSF-1 levels (Supplemental Figure 2K ) could reflect the correlation between type 1 IFN signalling and CSF-1 production.
Our studies do not confirm this however and more work is required to test this hypothesis.
Collectively, our data implicate a 'super-charged' monocytes as a potential driver in IPF, possibly by enhancing alveolar epithelial injury through the persistence of monocytes with a potentially injurious, primed type I IFN signalling in the lungs. Higher CD64 expression could be secondary to this enhanced type 1 IFN signalling, and the latter could also be the cause for the delayed macrophage differentiation. Whilst the data do not establish a causative relationship between the observations, these novel findings provide an impetus to move the mechanistic focus to immune pathways outside the lungs. Inhibiting or modulating CD64 expression could be a therapeutic possiblity in IPF, given the selective expression of CD64 on myeloid cells, and its high affinity for IgG, which makes antibody-mediated inhibition an attractive strategy The findings also emphasise the importance of infection, in driving progression of, and precipitating widespread damage and acceleration of fibrosis in IPF.
In summary, our study identifies and defines the key monocytic abnormalities in IPF, describing type 1 IFN primed monocytes as possible mediators that exacerbate injury which worsens an already aberrant repair process. We have identified increased levels of CD64 as a potential new theragnostic target for IPF. These findings provide fresh mechanistic insight into a devastating disease with limited therapeutic options.
Methods
Patient and control recruitment, and imaging methods in Supplemental Methods.
Isolation of PBMCs and monocytes
Blood samples were collected in lithium heparin (Greiner Bio-one) and processed within 4 hours. Peripheral blood mononuclear cells (PBMCs) were extracted by Lymphoprep TM (Axis-Shield) density gradient separation. Monocytes were isolated from PBMCs by positive selection using anti CD14 microbeads (Miltenyi Biotec) according to the manufacturer's instructions. Post separation CD14 + monocyte purity was assessed by flow cytometry (CD3, CD19, CD15, CD16 and CD14). Only samples with purity of greater than 98% were used. 
Serum preparation and soluble mediator analyses
Flow Cytometry
All antibodies were purchased from Biolegend, except Annexin V (eBiosciences). Cultured cells were incubated with Zombie Aqua fixable viability stain (Biolegend) to enable exclusion of dead cells from subsequent analysis. Cells were incubated with antibodies against surface antigens for 20 minutes at 4 o C and fixed with Stabilising Fixative (BD) prior to acquisition (52) .
For detection of CD68, cells were permeabilized with saponin (Sigma-Aldrich) and incubated with anti CD68 for 30 minutes at room temperature. Cells were acquired using a LSRFortessa™(BD) and data was analyzed using Flowjo v10 software (Tree star, Inc) and FACSDiva™(BD). 
IFN-b stimulation of cultured monocytes
Real-time PCR
For all qPCR phenotypic studies (Supplemental Table 4 and Figure 4 ), CD14 positivelyselected monocytes were lysed in RLT buffer (QIAGEN) supplemented with beta- FASTQ files were generated and quality of raw sequencing reads was initially assessed using fastQC (65) . Poor quality bases (<20) and technical sequences were trimmed using Cutadapt software and reads were subsequently aligned using STAR aligner (66) against the human genome hg38 assembly. Non-uniquely mapped reads were discarded and gene expression levels were quantified as read counts using the featureCounts function (67) from the Subread package (68) with default parameters. There were 27.4-38.3M final uniquely mappable reads per sample. The read counts were normalized using library size factors to account for differences in sequencing depth and/or RNA composition, calculated using the median ratio method, as described in Anders and Hubert (69) . Differential expression performed using the DESeq2 R package (70) . R package clusterProfiler (71) was used to perform enrichment studies on differentially expressed genes and GSEA (30) on all genes between the two groups, using gene sets from GO (72) (73) (74) and Reactome (75) pathways.
Significance threshold was set at 5% FDR in all cases.
Generation of monocyte-derived macrophages (MDMs)
Monocytes were cultured in X-VIVO TM (Lonza) supplemented with 10% autologous serum.
Cells were plated onto low-adherence plates (Corning) and cultured for 7 days. 50ng/ml human M-CSF (Miltenyi Biotec) was added on day 0 to promote monocyte survival. On day 7, plates were placed on ice for 20 minutes to detach monocytes which were then harvested by gentle pipetting, washed and counted.
Phagocytosis assay
pHrodo® Green E. coli bioparticle assay (Molecular Probes) was used according to manufacturer's instructions. Upon phagocytosis and transfer into the lysosome, the pH sensitive bioparticle emits a fluorescent signal. MDMs were incubated with pHrodo® Green E.
coli bioparticles for 30min at 37 o C, washed stained with viability dye Zombie Aqua (Biolegend), placed on ice before immediate flow cytometry analysis.
ROS assay
CM-H2DCFDA (Molecular Probes) was used according to manufacturer's instructions as indicator for reactive oxygen species (ROS) in cells. MDMs were cultured for 7 days as described above and incubated with 5 µM CM-H2DCFDA at 37 o C for 30min. Oxidative stress was induced using 0.03% H2O2 for 1 hour then cells were washed stained with viability dye Zombie Aqua (Biolegend) and placed on ice before immediate flow cytometry analysis.
Neutrophil efferocytosis assay
Neutrophils were isolated from whole blood using the MACSxpress isolation kit (Miltenyi input to a threshold classifier. As post-processing steps; a method for cell separation which is based on shape and size is used, cell areas that are too small are removed and finally applying unbiased counting frames to avoid the cells that are intersecting with neighbouring tile boundaries counted twice (or more).
Statistical analysis
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